Category: biotech

.Invite to this week’s Chutes &amp Ladders, our roundup of notable leadership hirings, shootings and retirings around the business. Please deliver the compliment– or the

.Bristol Myers Squibb is actually axing yet another major bet from the Caforio period, ending an offer for Agenus’ TIGIT bispecific antitoxin three years after

.Bristol Myers Squibb is spending Perfect Medicine $110 million beforehand to establish reagents for ex vivo T-cell therapies. Excellent, which could possibly get a tremendous

.Bristol Myers Squibb has possessed a whiplash change of heart on its own BCMA bispecific T-cell engager, stopping (PDF) more development months after filing to

.AvenCell Therapeutics has safeguarded $112 thousand in series B funds as the Novo Holdings-backed biotech finds scientific evidence that it may produce CAR-T tissues that

.Atea Pharmaceuticals’ antiviral has actually fallen short another COVID-19 trial, yet the biotech still keeps out wish the candidate has a future in liver disease

.Atea Pharmaceuticals’ antiviral has actually fallen short another COVID-19 trial, yet the biotech still keeps out wish the candidate has a future in liver disease

.Pinetree Therapies will assist AstraZeneca plant some plants in its pipeline along with a brand new deal to build a preclinical EGFR degrader worth $45

.AstraZeneca has settled CSPC Pharmaceutical Group $100 million for a preclinical heart disease drug. The offer, which covers a potential opponent to an Eli Lilly

.AstraZeneca has actually discussed an early take a look at the performance of its own in-house antibody-drug conjugate (ADC) innovation, releasing stage 1 data on